Effective April 1, 2018:
The mean final dose of SOLIQUA 100/33 and insulin glargine 100 Units/mL at Week 30 was equivalent—46.7 Units (for SOLIQUA 100/33: 46.7 Units insulin glargine/15.6 mcg lixisenatide).
The difference in effect observed in the trial may not necessarily reflect the effect that will be observed in the care setting where alternative insulin glargine dosage can be used.
For further details, please refer to the study design in the link below.
A total of 736 patients with T2DM participated in a randomized, 30-week, open-label, multicenter study to evaluate the efficacy and safety of SOLIQUA 100/33 compared to Lantus®.